Surgical Innovations Group plc Logo

Surgical Innovations Group plc

SUN.L

(2.0)
Stock Price

0,55 GBp

-6.53% ROA

-4.83% ROE

-11x PER

Market Cap.

4.664.081,00 GBp

10.62% DER

0% Yield

-4.24% NPM

Surgical Innovations Group plc Stock Analysis

Surgical Innovations Group plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Surgical Innovations Group plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.77x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (20%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

ROE in an average range (2.44%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (2.87%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Surgical Innovations Group plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Surgical Innovations Group plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Surgical Innovations Group plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Surgical Innovations Group plc Revenue
Year Revenue Growth
1989 66.000
1990 323.000 79.57%
1991 295.000 -9.49%
1992 676.000 56.36%
1993 1.124.000 39.86%
1994 212.000 -430.19%
1995 642.000 66.98%
1996 463.000 -38.66%
1998 1.669.000 72.26%
1999 1.255.000 -32.99%
2000 1.790.000 29.89%
2001 1.847.000 3.09%
2002 2.224.000 16.95%
2003 2.750.000 19.13%
2004 3.032.000 9.3%
2005 4.018.000 24.54%
2006 4.460.000 9.91%
2007 4.770.000 6.5%
2008 4.312.000 -10.62%
2009 4.541.000 5.04%
2010 7.045.000 35.54%
2011 7.602.000 7.33%
2012 7.639.000 0.48%
2013 8.553.000 10.69%
2014 4.029.000 -112.29%
2015 5.468.000 26.32%
2016 6.089.000 10.2%
2017 8.752.000 30.43%
2018 10.969.000 20.21%
2019 10.733.000 -2.2%
2019 10.733.000 0%
2020 6.329.000 -69.58%
2021 9.126.000 30.65%
2022 11.340.000 19.52%
2023 25.456.000 55.45%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Surgical Innovations Group plc Research and Development Expenses
Year Research and Development Expenses Growth
1989 0
1990 33.000 100%
1991 36.000 8.33%
1992 114.000 68.42%
1993 165.000 30.91%
1994 277.000 40.43%
1995 300.000 7.67%
1996 141.000 -112.77%
1998 61.000 -131.15%
1999 45.000 -35.56%
2000 25.000 -80%
2001 264.000 90.53%
2002 256.000 -3.13%
2003 318.000 19.5%
2004 330.000 3.64%
2005 248.000 -33.06%
2006 56.000 -342.86%
2007 41.000 -36.59%
2008 0 0%
2009 0 0%
2010 160.000 100%
2011 400.000 60%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 590.000 100%
2018 618.000 4.53%
2019 922.000 32.97%
2019 922.000 0%
2020 1.099.000 16.11%
2021 973.000 -12.95%
2022 1.164.000 16.41%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Surgical Innovations Group plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1.098.000 100%
2003 1.255.000 12.51%
2004 1.358.000 7.58%
2005 1.322.000 -2.72%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 645.000 100%
2015 260.000 -148.08%
2016 415.000 37.35%
2017 515.000 19.42%
2018 908.000 43.28%
2019 879.000 -3.3%
2019 879.000 0%
2020 790.000 -11.27%
2021 797.000 0.88%
2022 745.000 -6.98%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Surgical Innovations Group plc EBITDA
Year EBITDA Growth
1989 -207.000
1990 -733.000 71.76%
1991 -1.106.000 33.73%
1992 -1.286.000 14%
1993 -1.360.000 5.44%
1994 -2.029.000 32.97%
1995 -1.694.000 -19.78%
1996 -926.000 -82.94%
1998 -734.000 -26.16%
1999 -451.000 -62.75%
2000 13.000 3569.23%
2001 192.000 93.23%
2002 167.000 -14.97%
2003 287.000 41.81%
2004 445.000 35.51%
2005 617.000 27.88%
2006 964.000 36%
2007 995.000 3.12%
2008 1.145.000 13.1%
2009 950.000 -20.53%
2010 2.554.000 62.8%
2011 2.836.000 9.94%
2012 2.598.000 -9.16%
2013 2.348.000 -10.65%
2014 -8.303.000 128.28%
2015 -1.045.000 -694.55%
2016 1.409.000 174.17%
2017 1.962.000 28.19%
2018 1.969.000 0.36%
2019 1.079.000 -82.48%
2019 1.079.000 0%
2020 -1.505.000 171.69%
2021 367.000 510.08%
2022 628.000 41.56%
2023 384.000 -63.54%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Surgical Innovations Group plc Gross Profit
Year Gross Profit Growth
1989 66.000
1990 323.000 79.57%
1991 295.000 -9.49%
1992 676.000 56.36%
1993 1.124.000 39.86%
1994 212.000 -430.19%
1995 642.000 66.98%
1996 463.000 -38.66%
1998 811.000 42.91%
1999 712.000 -13.9%
2000 952.000 25.21%
2001 1.001.000 4.9%
2002 1.176.000 14.88%
2003 1.438.000 18.22%
2004 1.600.000 10.13%
2005 1.723.000 7.14%
2006 1.867.000 7.71%
2007 2.393.000 21.98%
2008 2.280.000 -4.96%
2009 1.894.000 -20.38%
2010 3.519.000 46.18%
2011 3.597.000 2.17%
2012 3.860.000 6.81%
2013 3.790.000 -1.85%
2014 1.186.000 -219.56%
2015 764.000 -55.24%
2016 2.060.000 62.91%
2017 3.719.000 44.61%
2018 4.672.000 20.4%
2019 4.333.000 -7.82%
2019 4.333.000 0%
2020 1.272.000 -240.64%
2021 3.131.000 59.37%
2022 3.922.000 20.17%
2023 5.780.000 32.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Surgical Innovations Group plc Net Profit
Year Net Profit Growth
1989 -225.000
1990 -893.000 74.8%
1991 -1.752.000 49.03%
1992 -1.687.000 -3.85%
1993 -2.128.000 20.72%
1994 -2.354.000 9.6%
1995 -2.515.000 6.4%
1996 -1.234.000 -103.81%
1998 -1.072.000 -15.11%
1999 -694.000 -54.47%
2000 -57.000 -1117.54%
2001 84.000 167.86%
2002 78.000 -7.69%
2003 139.000 43.88%
2004 212.000 34.43%
2005 402.000 47.26%
2006 696.000 42.24%
2007 765.000 9.02%
2008 630.000 -21.43%
2009 525.000 -20%
2010 1.788.000 70.64%
2011 1.738.000 -2.88%
2012 686.000 -153.35%
2013 800.000 14.25%
2014 -9.457.000 108.46%
2015 -2.033.000 -365.17%
2016 716.000 383.94%
2017 626.000 -14.38%
2018 725.000 13.66%
2019 -2.619.000 127.68%
2019 -2.619.000 0%
2020 -3.276.000 20.05%
2021 -456.000 -618.42%
2022 264.000 272.73%
2023 -540.000 148.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Surgical Innovations Group plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Surgical Innovations Group plc Free Cashflow
Year Free Cashflow Growth
1991 -2.554.000
1992 -1.488.000 -71.64%
1993 -1.865.000 20.21%
1994 -2.381.000 21.67%
1995 -1.981.000 -20.19%
1996 -1.028.000 -92.7%
1998 -1.155.000 11%
1999 -557.000 -107.36%
2000 -366.000 -52.19%
2001 -201.000 -82.09%
2002 -355.000 43.38%
2003 97.000 465.98%
2004 59.000 -64.41%
2005 166.000 64.46%
2006 244.000 31.97%
2007 -954.000 125.58%
2008 -954.000 0%
2009 -78.000 -1123.08%
2010 158.000 149.37%
2011 -1.072.000 114.74%
2012 -1.371.000 21.81%
2013 -775.000 -76.9%
2014 -2.086.000 62.85%
2015 1.059.000 296.98%
2016 2.244.000 52.81%
2017 833.000 -169.39%
2018 1.164.000 28.44%
2019 78.000 -1392.31%
2019 19.500 -300%
2020 887.000 97.8%
2021 -1.090.000 181.38%
2022 -592.000 -84.12%
2023 129.000 558.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Surgical Innovations Group plc Operating Cashflow
Year Operating Cashflow Growth
1991 -1.756.000
1992 -1.402.000 -25.25%
1993 -1.765.000 20.57%
1994 -2.320.000 23.92%
1995 -1.972.000 -17.65%
1996 -1.028.000 -91.83%
1998 -1.048.000 1.91%
1999 -440.000 -138.18%
2000 -309.000 -42.39%
2001 -113.000 -173.45%
2002 -148.000 23.65%
2003 255.000 158.04%
2004 80.000 -218.75%
2005 230.000 65.22%
2006 625.000 63.2%
2007 -428.000 246.03%
2008 7.000 6214.29%
2009 1.439.000 99.51%
2010 2.202.000 34.65%
2011 1.775.000 -24.06%
2012 612.000 -190.03%
2013 1.268.000 51.74%
2014 -485.000 361.44%
2015 1.506.000 132.2%
2016 2.845.000 47.07%
2017 1.608.000 -76.93%
2018 1.650.000 2.55%
2019 594.000 -177.78%
2019 148.500 -300%
2020 1.042.000 85.75%
2021 -433.000 340.65%
2022 486.000 189.09%
2023 512.000 5.08%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Surgical Innovations Group plc Capital Expenditure
Year Capital Expenditure Growth
1991 798.000
1992 86.000 -827.91%
1993 100.000 14%
1994 61.000 -63.93%
1995 9.000 -577.78%
1996 0 0%
1998 107.000 100%
1999 117.000 8.55%
2000 57.000 -105.26%
2001 88.000 35.23%
2002 207.000 57.49%
2003 158.000 -31.01%
2004 21.000 -652.38%
2005 64.000 67.19%
2006 381.000 83.2%
2007 526.000 27.57%
2008 961.000 45.27%
2009 1.517.000 36.65%
2010 2.044.000 25.78%
2011 2.847.000 28.21%
2012 1.983.000 -43.57%
2013 2.043.000 2.94%
2014 1.601.000 -27.61%
2015 447.000 -258.17%
2016 601.000 25.62%
2017 775.000 22.45%
2018 486.000 -59.47%
2019 516.000 5.81%
2019 129.000 -300%
2020 155.000 16.77%
2021 657.000 76.41%
2022 1.078.000 39.05%
2023 383.000 -181.46%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Surgical Innovations Group plc Equity
Year Equity Growth
1989 1.229.000
1990 335.000 -266.87%
1991 1.682.000 80.08%
1992 1.369.000 -22.86%
1993 5.319.000 74.26%
1994 2.754.000 -93.14%
1995 1.201.000 -129.31%
1996 201.000 -497.51%
1997 972.000 79.32%
1998 -68.000 1529.41%
1999 -762.000 91.08%
2000 1.056.000 172.16%
2001 1.141.000 7.45%
2002 1.248.000 8.57%
2003 1.395.000 10.54%
2004 1.650.000 15.45%
2005 2.094.000 21.2%
2006 2.799.000 25.19%
2007 7.410.000 62.23%
2008 8.040.000 7.84%
2009 8.640.000 6.94%
2010 10.588.000 18.4%
2011 12.616.000 16.07%
2012 13.563.000 6.98%
2013 14.515.000 6.56%
2014 6.119.000 -137.21%
2015 3.930.000 -55.7%
2016 5.838.000 32.68%
2017 13.716.000 57.44%
2018 14.423.000 4.9%
2019 12.192.000 -18.3%
2020 11.090.000 -9.94%
2021 10.664.000 -3.99%
2022 10.963.000 2.73%
2023 10.484.000 -4.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Surgical Innovations Group plc Assets
Year Assets Growth
1989 2.261.000
1990 1.369.000 -65.16%
1991 3.051.000 55.13%
1992 2.843.000 -7.32%
1993 6.639.000 57.18%
1994 3.964.000 -67.48%
1995 2.488.000 -59.32%
1996 713.000 -248.95%
1997 1.161.000 38.59%
1998 2.361.000 50.83%
1999 1.805.000 -30.8%
2000 1.675.000 -7.76%
2001 1.826.000 8.27%
2002 2.308.000 20.88%
2003 2.858.000 19.24%
2004 2.908.000 1.72%
2005 3.150.000 7.68%
2006 3.922.000 19.68%
2007 9.373.000 58.16%
2008 11.107.000 15.61%
2009 11.538.000 3.74%
2010 13.540.000 14.79%
2011 18.949.000 28.55%
2012 18.257.000 -3.79%
2013 20.647.000 11.58%
2014 11.274.000 -83.14%
2015 7.770.000 -45.1%
2016 6.834.000 -13.7%
2017 18.539.000 63.14%
2018 18.830.000 1.55%
2019 16.311.000 -15.44%
2020 16.343.000 0.2%
2021 15.718.000 -3.98%
2022 15.595.000 -0.79%
2023 14.320.000 -8.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Surgical Innovations Group plc Liabilities
Year Liabilities Growth
1989 1.032.000
1990 1.034.000 0.19%
1991 1.369.000 24.47%
1992 1.474.000 7.12%
1993 1.320.000 -11.67%
1994 1.210.000 -9.09%
1995 1.287.000 5.98%
1996 512.000 -151.37%
1997 189.000 -170.9%
1998 2.429.000 92.22%
1999 2.567.000 5.38%
2000 619.000 -314.7%
2001 685.000 9.64%
2002 1.060.000 35.38%
2003 1.463.000 27.55%
2004 1.258.000 -16.3%
2005 1.056.000 -19.13%
2006 1.123.000 5.97%
2007 1.963.000 42.79%
2008 3.067.000 36%
2009 2.898.000 -5.83%
2010 2.952.000 1.83%
2011 6.333.000 53.39%
2012 4.694.000 -34.92%
2013 6.132.000 23.45%
2014 5.155.000 -18.95%
2015 3.840.000 -34.24%
2016 996.000 -285.54%
2017 4.823.000 79.35%
2018 4.407.000 -9.44%
2019 4.119.000 -6.99%
2020 5.253.000 21.59%
2021 5.054.000 -3.94%
2022 4.632.000 -9.11%
2023 3.836.000 -20.75%

Surgical Innovations Group plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0
Price to Earning Ratio
-11x
Price To Sales Ratio
0.39x
POCF Ratio
13.99
PFCF Ratio
-16.19
Price to Book Ratio
0.53
EV to Sales
0.43
EV Over EBITDA
30.26
EV to Operating CashFlow
12.79
EV to FreeCashFlow
-17.76
Earnings Yield
-0.09
FreeCashFlow Yield
-0.06
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
-0.79
ROE
-0.05
Return On Assets
-0.04
Return On Capital Employed
-0.05
Net Income per EBT
0.7
EBT Per Ebit
1.24
Ebit per Revenue
-0.05
Effective Tax Rate
0.3

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
-0.05
Pretax Profit Margin
-0.06
Net Profit Margin
-0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
-0
Capex to Operating CashFlow
1.72
Capex to Revenue
0.06
Capex to Depreciation
0.91
Return on Invested Capital
-0.04
Return on Tangible Assets
-0.07
Days Sales Outstanding
48.43
Days Payables Outstanding
48.24
Days of Inventory on Hand
117.77
Receivables Turnover
7.54
Payables Turnover
7.57
Inventory Turnover
3.1
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,01
Tangible Book Value per Share
0
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0.11
Debt to Assets
0.08
Net Debt to EBITDA
2.66
Current Ratio
2.32
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
11700000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.46
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
3210000
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Surgical Innovations Group plc Dividends
Year Dividends Growth

Surgical Innovations Group plc Profile

About Surgical Innovations Group plc

Surgical Innovations Group plc, together with its subsidiaries, designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The company's SI Brand segment researches, develops, manufactures, and distributes SI branded minimally invasive devices. This segment also offers YelloPort Elite and YelloPort +plus laparoscopic port access systems; LogiRange resposable laparoscopic instrument systems; FastClamp laparoscopic clamping systems; and QuickRange single use laparoscopic instrumentation. Its OEM segment researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through own label or co-branding. This segment also provides design and development solutions for producing a final device; and researches, develops, manufactures, and sells minimally invasive technology products for precision engineering applications. The company's Distribution segment distributes medical products through Elemental Healthcare Ltd. It also designs and manufactures autologous blood products. It sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was incorporated in 1988 and is based in Leeds, the United Kingdom.

CEO
Mr. David John Marsh
Employee
80
Address
Clayton Wood House
Leeds, LS16 6QZ

Surgical Innovations Group plc Executives & BODs

Surgical Innovations Group plc Executives & BODs
# Name Age
1 Mr. Stephen Seed
Chief Compliance Officer
70
2 Julia Horrocks Taylor
HR Director
70
3 Mr. Christopher Jonathan Martin
Chief Financial Officer & Executive Director
70
4 Mr. Alex Hogg
Operations Director
70
5 Mr. Damian Donnelly
Chief Commercial Officer
70
6 Mr. David John Marsh
Chief Executive Officer & Director
70

Surgical Innovations Group plc Competitors